CAR-T trial deaths do not deter lupus patients hoping for a cure
Executive Brief • Key Highlights
Fast factual intelligence distilled for busy investors, executives, and answer bots:
- ✓Lupus patients are lining up for experimental CAR-T therapies despite four recent deaths in clinical trials.
- ✓Many hope for a cure as current treatments often fail to control the disease.
- ✓"I have patients that are literally waiting to get in," said Dr.
Story at a Glance
- Category
- Indian Markets
- Reported By
- Reuters
- Reading Speed
- 5 Minute(s)
- Market Focus
- India Economy
CHICAGO, Nov 11 (Reuters) - Lupus patients struggling with the debilitating disease are lining up to try experimental CAR-T therapies even after the recent deaths of four patients in clinical trials for a variety of autoimmune diseases, according to doctors who treat the life-threatening condition.
Sign up here.
Still, patients are willing to take the risk, compelled by accounts of people with advanced disease who were able to stop all medications and reclaim normal lives.
"I have patients that are literally waiting to get in," said Dr. Anca Askanase, chief of rheumatology at the Hospital for Special Surgery in New York, who has enrolled patients in the Bristol Myers CAR-T trials.
Unlock the Full Story with ArthNow Premium
To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.
Reuters
Read the full, original unfiltered story directly on the publisher's portal.
This brief is for information only and is not investment advice. ArthNow is not a SEBI-registered investment adviser and does not publish buy or sell recommendations. Original reporting is credited to the publisher named above. Read our editorial policy or report an error.